Back to Newsroom

Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association

CORAL GABLES, Fla., Oct. 8, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst’s Phase 3 FirdapseTM trial at the 139th Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, “A Phase 3 Trial of Firdapse™ Tablets in Lambert-Eaton Myasthenic Syndrome,” to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12th at 5:20 pm (EDT). In addition, the Company will have a poster presentation (Poster #S737WIP) at the conference from 5:30 to 7:00 pm EDT. The presentation materials will be posted at in the Investors section under Events & Presentations.

Click here to read more